Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2023-05-10 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Interim financial statements/report (amended) - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Refiling of Condensed Interim Consolidated Financial Statements for the Six-month period ended January 31, 2023." It contains detailed financial statements including statements of financial position, net loss and comprehensive loss, changes in equity, and cash flows for the six-month period ended January 31, 2023. The document also includes notes to the condensed interim consolidated financial statements, significant accounting policies, and management's discussion of going concern and estimates. The presence of unaudited interim financial statements prepared under International Accounting Standard 34 (Interim Financial Reporting) confirms this is an interim report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-05-10 English
News release - French.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the approval of modifications to the company's stock option plan and restricted share unit plan by shareholders at the annual and extraordinary general meeting held on March 17, 2023. It details the changes made to comply with TSX Venture Exchange policies and includes references to shareholder approval and regulatory compliance. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, audit report, or earnings release. It is an announcement related to governance and shareholder approval of equity compensation plans. Given the content focuses on shareholder approval results and plan modifications, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not merely a notice of a report publication but a substantive announcement of shareholder approval outcomes. Confidence is high due to clear references to shareholder meeting results and plan approvals.
2023-03-30 English
News release - English.pdf
Board/Management Information Classification · 90% confidence The document is a press release announcing the approval of amendments to the company's stock option plan and restricted share unit plan at the annual and special meeting of shareholders. It discusses compliance with exchange policies, details of the amended plans, and references the management and information circular where the full plans are available. There is no presentation of financial statements or detailed financial performance data. The document is an announcement related to governance and shareholder meeting outcomes but does not contain the full management circular or detailed governance report itself. It is not a full Annual Report, Interim Report, or Management Report. It is also not a Proxy Solicitation or Voting Results announcement. The content focuses on governance-related plan amendments approved at a shareholder meeting, which aligns best with Board/Management Information (MANG) as it relates to changes in company governance plans and approvals by shareholders. The document length and content indicate it is more than a brief announcement but does not contain full financial or governance reports, so MANG is the best fit.
2023-03-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the Interim CFO of Devonian Health Group Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3101 characters), consistent with a certification letter rather than a full report.
2023-03-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2023. It is a certification letter rather than the actual interim report or financial statements. The document length is short (3053 characters) and primarily contains officer certification language without substantive financial data or analysis. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2023-03-24 English
52-109FV2 - Certification of interim filings - CFO (F).pdf
Regulatory Filings Classification · 95% confidence The document is an attestation by the interim Chief Financial Officer regarding the review of the interim financial report and management report for the period ended January 31, 2023. It explicitly states it is an attestation for an emerging issuer under Canadian regulation 52-109, confirming the accuracy and fair presentation of the interim financial documents. The document does not contain the actual financial statements or substantive financial data but is a certification or attestation related to the interim report. According to the Certification Rule, such attestations should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3653 characters, which is relatively short and consistent with an attestation letter rather than a full interim report.
2023-03-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.